Evaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin

Yang Zhao, MinKe He, RunBin Liang, QiJiong Li, Ming Shi Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of ChinaCorrespondence: Min...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhao Y, He M, Liang R, Li Q, Shi M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	aprepitant chemotherapy-induced nausea and vomiting hepatocellular carcinoma hepatic arterial infusion chemotherapy Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/cff7c3bc0a5a42408c622885c258bb8d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cff7c3bc0a5a42408c622885c258bb8d
record_format	dspace
spelling	oai:doaj.org-article:cff7c3bc0a5a42408c622885c258bb8d2021-12-02T13:51:18ZEvaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin1178-203Xhttps://doaj.org/article/cff7c3bc0a5a42408c622885c258bb8d2021-01-01T00:00:00Zhttps://www.dovepress.com/evaluation-of-antiemetic-therapy-for-hepatic-arterial-infusion-chemoth-peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XYang Zhao, MinKe He, RunBin Liang, QiJiong Li, Ming Shi Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of ChinaCorrespondence: Ming ShiDepartment of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, People’s Republic of ChinaTel/Fax +86-020-87343938Email shiming@sysu.edu.cnPurpose: Our aim was to compare the antiemetic efficacy of the triple combination of aprepitant, dolasetron and dexamethasone with the combination of dolasetron and dexamethasone for chemotherapy-induced nausea and vomiting (CINV) in hepatocellular carcinoma (HCC) patients receiving hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil and leucovorin (FOLFOX).Patients and Methods: This was a retrospective study. In the dolasetron plus dexamethasone group (D group), the patients received dolasetron (100 mg, i.v., on day 1) and dexamethasone (10 mg, i.v., on day 1) 30 min before starting administration of chemotherapeutic drugs. In the aprepitant plus dolasetron and dexamethasone group (AD group), the patients received dolasetron and dexamethasone as described above, and aprepitant (125 mg, p.o.) on day 1 followed by 80 mg on days 2 and 3. The primary endpoint was the complete response rate (CR, defined as no emetic episodes and no rescue medication use) during the first cycle of hepatic arterial infusion chemotherapy.Results: Between January 2018 and August 2019, 302 eligible patients were included: 197 in AD group and 105 in D group. Patients in AD group had significantly higher complete response rates than those in D group during the first cycle (85.8% vs 71.4%, P = 0.003) and all cycles (73.6% vs 49.5%, P< 0.001). Patients in AD group had lower rescue therapy (1.5% vs 26.7%, P< 0.001) and lower incidence of disruption related to chemotherapy-induced nausea and vomiting (0.5% vs 6.7%, P = 0.002) than patients in D group.Conclusion: Aprepitant, dolasetron plus dexamethasone is more effective to prevent chemotherapy-induced nausea and vomiting in hepatocellular carcinoma patients treated with FOLFOX-HAIC therapy than dolasetron plus dexamethasone.Keywords: aprepitant, chemotherapy-induced nausea and vomiting, hepatocellular carcinoma, hepatic arterial infusion chemotherapyZhao YHe MLiang RLi QShi MDove Medical Pressarticleaprepitantchemotherapy-induced nausea and vomitinghepatocellular carcinomahepatic arterial infusion chemotherapyTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 17, Pp 73-77 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	aprepitant chemotherapy-induced nausea and vomiting hepatocellular carcinoma hepatic arterial infusion chemotherapy Therapeutics. Pharmacology RM1-950
spellingShingle	aprepitant chemotherapy-induced nausea and vomiting hepatocellular carcinoma hepatic arterial infusion chemotherapy Therapeutics. Pharmacology RM1-950 Zhao Y He M Liang R Li Q Shi M Evaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin
description	Yang Zhao, MinKe He, RunBin Liang, QiJiong Li, Ming Shi Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of ChinaCorrespondence: Ming ShiDepartment of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, People’s Republic of ChinaTel/Fax +86-020-87343938Email shiming@sysu.edu.cnPurpose: Our aim was to compare the antiemetic efficacy of the triple combination of aprepitant, dolasetron and dexamethasone with the combination of dolasetron and dexamethasone for chemotherapy-induced nausea and vomiting (CINV) in hepatocellular carcinoma (HCC) patients receiving hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil and leucovorin (FOLFOX).Patients and Methods: This was a retrospective study. In the dolasetron plus dexamethasone group (D group), the patients received dolasetron (100 mg, i.v., on day 1) and dexamethasone (10 mg, i.v., on day 1) 30 min before starting administration of chemotherapeutic drugs. In the aprepitant plus dolasetron and dexamethasone group (AD group), the patients received dolasetron and dexamethasone as described above, and aprepitant (125 mg, p.o.) on day 1 followed by 80 mg on days 2 and 3. The primary endpoint was the complete response rate (CR, defined as no emetic episodes and no rescue medication use) during the first cycle of hepatic arterial infusion chemotherapy.Results: Between January 2018 and August 2019, 302 eligible patients were included: 197 in AD group and 105 in D group. Patients in AD group had significantly higher complete response rates than those in D group during the first cycle (85.8% vs 71.4%, P = 0.003) and all cycles (73.6% vs 49.5%, P< 0.001). Patients in AD group had lower rescue therapy (1.5% vs 26.7%, P< 0.001) and lower incidence of disruption related to chemotherapy-induced nausea and vomiting (0.5% vs 6.7%, P = 0.002) than patients in D group.Conclusion: Aprepitant, dolasetron plus dexamethasone is more effective to prevent chemotherapy-induced nausea and vomiting in hepatocellular carcinoma patients treated with FOLFOX-HAIC therapy than dolasetron plus dexamethasone.Keywords: aprepitant, chemotherapy-induced nausea and vomiting, hepatocellular carcinoma, hepatic arterial infusion chemotherapy
format	article
author	Zhao Y He M Liang R Li Q Shi M
author_facet	Zhao Y He M Liang R Li Q Shi M
author_sort	Zhao Y
title	Evaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin
title_short	Evaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin
title_full	Evaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin
title_fullStr	Evaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin
title_full_unstemmed	Evaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin
title_sort	evaluation of antiemetic therapy for hepatic arterial infusion chemotherapy with oxaliplatin, fluorouracil, and leucovorin
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/cff7c3bc0a5a42408c622885c258bb8d
work_keys_str_mv	AT zhaoy evaluationofantiemetictherapyforhepaticarterialinfusionchemotherapywithoxaliplatinfluorouracilandleucovorin AT hem evaluationofantiemetictherapyforhepaticarterialinfusionchemotherapywithoxaliplatinfluorouracilandleucovorin AT liangr evaluationofantiemetictherapyforhepaticarterialinfusionchemotherapywithoxaliplatinfluorouracilandleucovorin AT liq evaluationofantiemetictherapyforhepaticarterialinfusionchemotherapywithoxaliplatinfluorouracilandleucovorin AT shim evaluationofantiemetictherapyforhepaticarterialinfusionchemotherapywithoxaliplatinfluorouracilandleucovorin
_version_	1718392406073671680

Evaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin

Ejemplares similares